文献速递贫血与红细胞疾病

羧基麦芽糖铁治疗非髓系恶性肿瘤化疗相关贫血的随机对照研究

Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, placebo-controlled study (IRON-CLAD).
PubMed 文献 · Am J Hematol · 2021-11-19

IRON-CLAD 研究是一项 3 期双盲安慰剂对照试验,纳入 244 例非髓系恶性肿瘤化疗相关贫血患者。羧基麦芽糖铁(FCM)单药治疗使第 3 至 18 周血红蛋白下降 ≥0.5 g/dL 的患者比例显著低于安慰剂(50.8% vs 35.3%,p=0.01),且耐受性良好。

要点

  • FCM 单药可有效维持化疗相关贫血患者的血红蛋白水平。
  • 基线 Hb≤9.9 g/dL 者 FCM 组 Hb 提升显著优于安慰剂。
  • FCM 组常见不良事件为中性粒细胞减少、低磷血症和乏力。

核心结论

  • 羧基麦芽糖铁单药治疗可有效维持非髓系恶性肿瘤化疗相关贫血患者的血红蛋白水平,且耐受性良好。

研究设计与样本

  • 3 期、18 周、双盲、安慰剂对照研究,随机纳入 244 例非髓系恶性肿瘤化疗相关贫血成人患者,每组 122 例。

主要发现

  • 第 3 至 18 周维持 Hb 在基线 0.5 g/dL 范围内的患者比例 FCM 组显著高于安慰剂组(50.8% vs 35.3%,p=0.01)。
  • 基线至第 18 周 Hb 平均变化 FCM 与安慰剂相似(1.04 vs 0.87 g/dL),但基线 Hb≤9.9 g/dL 者 FCM 组显著更优(1.08 vs 0.42 g/dL,p=0.01)。
  • Hb 较基线增加 ≥1 g/dL 的患者比例 FCM 组显著更高(71% vs 54%,p=0.01),中位发生时间分别为 43 天与 85 天(p=0.001)。
  • FCM 组常见不良事件包括中性粒细胞减少(17%)、低磷血症(16%)和乏力(15%)。

关键数值与推荐

  • 纳入标准:Hb 8-11 g/dL,铁蛋白 100-800 ng/mL,转铁蛋白饱和度(TSAT)≤35%。
  • FCM 给药方案:两次 15 mg/kg 输注,间隔 7 天;单次最大剂量 750 mg,总最大剂量 1500 mg。

临床怎么用

  • 对于非髓系恶性肿瘤化疗相关贫血且铁蛋白 100-800 ng/mL、TSAT≤35% 的患者,可考虑 FCM 单药治疗以维持 Hb。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Erythropoiesis-stimulating agents (ESA) are effective for chemotherapy-induced anemia (CIA) but associated with serious adverse events. Safer alternatives would be beneficial in this population. The efficacy and safety of ferric carboxymaltose (FCM) as monotherapy for CIA was evaluated. This Phase 3, 18-week, double-blind, placebo-controlled study randomized adults with ≥ 4 weeks of chemotherapy remaining for treatment of nonmyeloid malignancies with CIA to FCM (two 15 mg/kg infusions 7 days apart; maximum dose, 750 mg single/1500 mg total) or placebo. The primary efficacy endpoint was percentage of patients with decreases in hemoglobin (Hb) ≥ 0.5 g/dL from weeks 3 to 18; the key secondary efficacy endpoint was change in Hb from baseline to week 18. Inclusion criteria included: (Hb) 8-11 g/dL, ferritin 100-800 ng/mL, and transferrin saturation (TSAT) ≤35%. In 244 patients (n = 122, both groups), the percent of patients who maintained Hb within 0.5 g/dL of baseline from weeks 3 to 18 was significantly higher with FCM versus placebo (50.8% vs. 35.3%; p = 0.01). Mean change in Hb from baseline to week 18 was similar between FCM and placebo (1.04 vs. 0.87 g/dL) but significantly greater with FCM with baseline Hb ≤ 9.9 g/dL (1.08 vs. 0.42 g/dL; p = 0.01). The percent with ≥ 1 g/dL increase from baseline was significantly higher with FCM versus placebo (71% vs. 54%; p = 0.01), occurring in a median 43 versus 85 days (p = 0.001). Common adverse events in the FCM arm included neutropenia (17%), hypophosphatemia (16%), and fatigue (15%). FCM monotherapy effectively maintained Hb and was well tolerated in CIA.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Makharadze T, Boccia R, Krupa A, et al. Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, placebo-controlled study (IRON-CLAD). Am J Hematol. 2021. PMID: 34653287. doi:10.1002/ajh.26376

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。